By Ben GlickmanShares of TG Therapeutics rose early Wednesday after the company forecast a sharp increase in annual revenue from its multiple sclerosis treatment. The stock was up 10.2% to $23.15 in pre-market trading. Shares have nearly tripled over the last three months.

Source: Wall Street Journal January 10, 2024 15:25 UTC